What question did this study set out to answer?

To determine the effects of the GLP-1 receptor agonist liraglutide on heart rate variability and diurnal heart rate variation in overweight individuals with stable coronary artery disease and newly diagnosed type 2 diabetes.

October 19, 2016Diabetes CareOpen Access

Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

Q: What are the key findings of this study?

Liraglutide increased mean heart rate by 8.1 beats/min and decreased heart rate variability (SDNN) by 33.9 ms in patients with type 2 diabetes and coronary artery disease (P < 0.001).

Q: What does this research mean for the field?

Liraglutide increased mean heart rate by 8.1 beats/min and decreased heart rate variability (SDNN) by 33.9 ms in patients with type 2 diabetes and coronary artery disease (P < 0.001). Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

View Full Paper

Ask AI

Bookmark

Key result

Liraglutide increases mean heart rate by ~8 bpm and reduces HRV in T2D with CAD.

P < 0.001

Why the study?

Does liraglutide affect heart rate and heart rate variability in overweight patients with newly diagnosed type 2 diabetes and stable coronary artery disease?

Population

27 overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD)

Comparison

Liraglutide added to a backbone therapy of… vs Matching placebo added to a backbone therapy of…

Design

RCT, Randomized crossover design, Double-blind

Follow-up

12 + 12 weeks (crossover)

Authors

PKPreman KumarathuraiUniversity of Southern Denmark CAChristian AnholmAmager Hospital BLBjørn Strøier LarsenUniversity of Copenhagen

Discussion

Member takes

Overview

May warrant autonomic monitoring with liraglutide in T2D and CAD; challenges consensus on neutral effects and leaves implications open.

Key Points

To determine the effects of the GLP-1 receptor agonist liraglutide on heart rate variability and diurnal heart rate variation in overweight individuals with stable coronary artery disease and newly diagnosed type 2 diabetes.
Conducted a double-blind, placebo-controlled 12 + 12–week crossover trial evaluating liraglutide versus placebo added to background metformin therapy in 27 overweight patients with type 2 diabetes and coronary artery disease.
Assessed autonomic function and sympathovagal balance via 24-hour Holter monitoring to measure SDNN, RMSSD, and frequency-domain measures (LF and HF power).
Liraglutide significantly decreased SDNN (-33.9 ms; P < 0.001) and RMSSD (-0.3 log-ms; P = 0.025) compared with placebo, and the reduction in SDNN persisted after multivariable adjustment for heart rate and metabolic changes.
Liraglutide significantly increased mean 24-hour heart rate (+8.1 beats/min; P = 0.003) and nighttime heart rate (+6.3 beats/min; P = 0.026), alongside an increase in daytime heart rate (+5.7 beats/min; P = 0.083).
High-frequency (HF) power was significantly reduced by liraglutide (-0.7 log-ms²; P = 0.026), with no significant change observed in the LF/HF ratio.

Structured PICO

Does liraglutide affect heart rate and heart rate variability in overweight patients with newly diagnosed type 2 diabetes and stable coronary artery disease?

Population

27 overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD)

Intervention

Liraglutide added to a backbone therapy of metformin

Comparator

Matching placebo added to a backbone therapy of metformin

Outcome

Standard deviation of beat-to-beat (NN) intervals (SDNN) assessed by 24-h Holter monitoring as a measure of heart rate variability (HRV)surrogate

In overweight patients with T2D and stable CAD, liraglutide increases heart rate and reduces heart rate variability, suggesting an alteration in sympathovagal balance despite metabolic improvements.

Cite This Study

Kumarathurai et al. (2016) studied this question. Liraglutide increased mean heart rate by 8.1 beats/min and decreased heart rate variability (SDNN) by 33.9 ms in patients with type 2 diabetes and coronary artery disease (P < 0.001).

synapsesocial.com/papers/697cda2ac8731042648bd920 https://doi.org/10.2337/dc16-1580

View Full Paper

Ask AI

Bookmark

October 19, 2016Diabetes CareOpen Access

Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

View Full Paper

Ask AI

Bookmark

Key result

Liraglutide increases mean heart rate by ~8 bpm and reduces HRV in T2D with CAD.

P < 0.001

Why the study?

Does liraglutide affect heart rate and heart rate variability in overweight patients with newly diagnosed type 2 diabetes and stable coronary artery disease?

Population

27 overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD)

Comparison

Liraglutide added to a backbone therapy of… vs Matching placebo added to a backbone therapy of…

Design

RCT, Randomized crossover design, Double-blind

Follow-up

12 + 12 weeks (crossover)

Authors

PKPreman KumarathuraiUniversity of Southern Denmark CAChristian AnholmAmager Hospital BLBjørn Strøier LarsenUniversity of Copenhagen

Discussion

Member takes

Overview

May warrant autonomic monitoring with liraglutide in T2D and CAD; challenges consensus on neutral effects and leaves implications open.

Key Points

To determine the effects of the GLP-1 receptor agonist liraglutide on heart rate variability and diurnal heart rate variation in overweight individuals with stable coronary artery disease and newly diagnosed type 2 diabetes.
Conducted a double-blind, placebo-controlled 12 + 12–week crossover trial evaluating liraglutide versus placebo added to background metformin therapy in 27 overweight patients with type 2 diabetes and coronary artery disease.
Assessed autonomic function and sympathovagal balance via 24-hour Holter monitoring to measure SDNN, RMSSD, and frequency-domain measures (LF and HF power).
Liraglutide significantly decreased SDNN (-33.9 ms; P < 0.001) and RMSSD (-0.3 log-ms; P = 0.025) compared with placebo, and the reduction in SDNN persisted after multivariable adjustment for heart rate and metabolic changes.
Liraglutide significantly increased mean 24-hour heart rate (+8.1 beats/min; P = 0.003) and nighttime heart rate (+6.3 beats/min; P = 0.026), alongside an increase in daytime heart rate (+5.7 beats/min; P = 0.083).
High-frequency (HF) power was significantly reduced by liraglutide (-0.7 log-ms²; P = 0.026), with no significant change observed in the LF/HF ratio.

Structured PICO

Does liraglutide affect heart rate and heart rate variability in overweight patients with newly diagnosed type 2 diabetes and stable coronary artery disease?

Population

27 overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD)

Intervention

Liraglutide added to a backbone therapy of metformin

Comparator

Matching placebo added to a backbone therapy of metformin

Outcome

Standard deviation of beat-to-beat (NN) intervals (SDNN) assessed by 24-h Holter monitoring as a measure of heart rate variability (HRV)surrogate

In overweight patients with T2D and stable CAD, liraglutide increases heart rate and reduces heart rate variability, suggesting an alteration in sympathovagal balance despite metabolic improvements.

Cite This Study

synapsesocial.com/papers/697cda2ac8731042648bd920 https://doi.org/10.2337/dc16-1580

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark